AIM News & Events

AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas Equels states: "The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca's durvalumab in the treatment of late-stage pancreatic cancer is producing promising results. Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM's development of Ampligen as a therapy for pancreatic cancer. AIM's scientific team will work closely with Thermo Fisher's experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor. Pancreatic cancer is a deadly unmet medical need - and AIM believes that Ampligen could be a gamechanger in the treatment of pancreatic cancer."

AIM ImmunoTech announced updated terms for its previously announced rights offering. Each subscription right now entitles holders to purchase one unit, each Unit consisting of one share of the Company's Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 1,000 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock divided by the conversion price. Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.00 per share from the date of issuance through its expiration five years from the date of issuance. All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any over-subscription privilege election, to the Subscription Agent, to be received before 5:00 p.m. Eastern Time on March 3, 2026.

AIM ImmunoTech has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The subscription period for the rights offering commenced on February 11, 2026. All holders of subscription rights that wish to subscribe to the rights offering must deliver a properly completed and signed subscription rights certificate, together with payment of the full subscription price for the units the holder wishes to purchase pursuant to both the basic subscription right and the over-subscription privilege, to Broadridge Corporate Issuer Solutions, to be received before 5:00 p.m., Eastern Time, on March 3, 2026.